

Essence Edition of Public Information Observatory

本资料由(上市公司)罗丽芬-KY 公司提供

This document is provided by (listed company) Luo Lih-Fen-KY Company

序号 S.N.	4	发言日期 Date of speech	109/06/03 (2020/06/03)	发言时间 Time of speech	16:21:34
发言人 Spokesperson	林怡君 Lin Yijun	发言人职称 Title of spokesperson	执行长特助 Special Assistant to the CEO	发言人电话 Spokesperson's phone number	(02)8773-9269
主旨 Purpose	本公司股东常会通过解除本公司第三届新任董事(含独立董事)及其代表人竞业禁止限制 Announcement of lifting non-competitive limitations of the 3 rd term new board of directors (including independent directors) on shareholders' general meeting.				
符合条款 Applicable term	第 21 款 Term 21	事实发生日 Date of occurrence of the event	109/06/03 (2020/06/03)		
说明 Descriptions	<p>1. 股东会决议日:109/06/03 1. Date of the shareholders' meeting resolution: 109/06/03 (2020/06/03)</p> <p>2. 许可从事竞业行为之董事姓名及职称: (1) 法人董事: 嘉黛国际有限公司 (代表人罗丽芬女士) (2) 法人董事: 赋达(香港)有限公司(代表人饶焕文先生) (3) 董事: 贺士郡先生 (4) 董事: 林丽珍女士 (5) 独立董事: 许英杰先生</p> <p>2. Name and title of the director with permission to engage in competitive conduct: (1) Juristic-person director: Black Praise International Limited Company (Representative: Luo Lih-Fen) (2) Juristic-person director: Talent Reach (HK) Limited Company (Representative: Huanwen Rao) (3) Director: Shijun He (4) Director: Lizhen Lin (5) Independent Director: Yingjie Xu</p> <p>3. 许可从事竞业行为之项目: 3. Items of competitive conduct which the director is permitted to engage in: (1) 自就任之日起, 如有台湾公司法 209 条竞业禁止之行为, 当在无损及本公司利益之前提下, 解除其竞业禁止限制。 (1) From the date of assuming office, if there is any action prohibited by Article 209 of the Taiwan Company Act, the non-competitive limitations shall be lifted without harming the interests of the company. (2) 当前兼任其他公司之职务解除其于竞业禁止限制明细如下 (2) The details of the lifting of non-competitive limitations to who also work in other companies are as follows: 法人董事嘉黛国际有限公司代表人罗丽芬女士: 漳州开普生物科技有限公司监事 立弘生化科技(股)公司董事 罗丽芬事业有限公司董事 丽瑞嘉生技股份有限公司董事 Juristic-person director: representative of Black Praise International Limited Company: Luo Lih-Fen: Supervisor of Zhangzhou Kaipu Biotech Co., Ltd.</p>				

Director of Allied Biotech Corporation

Director of Luo Lih-Fen Holding Group

Director of Li Ruijia Biotech Co., Ltd.

法人董事赋达(香港)有限公司代表人饶焕文先生:

罗丽芬集团有限公司董事

嘉文丽(福建)化妆品有限公司执行董事

漳州开普生物科技有限公司执行董事兼总经理

汇文丽(福建)企业管理有限公司执行董事

丽创(福建)生物科技有限公司执行董事

Juristic-person director: representative of Talent Reach (HK) Limited Company: Huanwen Rao

Director of Luo Lih-Fen Group

Executive director of Juwenlee (Fujian) Cosmetics Co.,Ltd

Executive director and general manager of Zhangzhou Kaipu Biotech Co., Ltd.

Executive director of Hui Wenli (Fujian) Enterprise Management Co., Ltd.

Executive director of Li Chuang (Fujian) Biotech Co., Ltd.

董事贺士郡先生:

长圣国际生技(股)公司董事

晟德大药厂(股)公司独立董事

立弘生化科技(股)公司董事

Director: Shijun He

Director of Ever Supreme Bio Technology Co., Ltd.

Independent director of Center Laboratories Inc.

Director of Allied Biotech Corporation

董事林丽珍女士:

华联生物科技(股)公司董事

Director: Lizhen Lin

Director of Phalanx biotech Co., Ltd.

独立董事许英杰先生:

立弘生化科技(股)公司独立董事/审计委员/薪酬委员

Independent director: Yingjie Xu

Independent director/ member of the audit committee/ member of remuneration committee of Allied Biotech Corporation

4. 许可从事竞业行为之期间:任职期间。

4. Period of permission to engage in the competitive conduct: Within the period of serving as the Director of the company.

5. 决议情形 (请依公司法第 209 条说明表决结果):赞成权数已超过表决时总表决权数的三分之二, 本案照案通过。

5. Circumstances of the resolution (please describe the results of the voting under Article 209 of the Company Act): The number of pro-vote stakes exceeds two-thirds of the total number of votes at the time of the voting, and the resolution was adopted.

6. 所许可之竞业行为如属大陆地区事业之营业者, 董事姓名及职称: (非属大陆地区事业之营业者, 以下请输“不适用”):

6. If the permitted competitive conduct is a business of mainland China area enterprise, the name and title of director (if it is not a business of mainland China area enterprise, please enter “not applicable” below): Not applicable:

法人董事嘉黛国际有限公司:代表人罗丽芬女士

法人董事赋达(香港)有限公司:代表人饶焕文先生
 Juristic-person director: representative of Black Praise International Limited Company: Luo Lih-Fen:

法人董事嘉黛国际有限公司代表人罗丽芬女士:
 Juristic-person director: representative of Talent Reach (HK) Limited Company: Huanwen Rao

7.所担任该大陆地区事业之公司名称及职务:
 7. Company name of the mainland China area enterprise and the director's position in the enterprise:

漳州开普生物科技有限公司监事
 Supervisor of Zhangzhou Kaipu Biotech Co., Ltd.

法人董事赋达(香港)有限公司代表人饶焕文先生:
 Juristic-person director: representative of Black Praise International Limited Company: Luo Lih-Fen:

嘉文丽(福建)化妆品有限公司执行董事
 Executive director of Juwenlee (Fujian) Cosmetics Co., Ltd.

漳州开普生物科技有限公司执行董事兼总经理
 Executive director and general manager of Zhangzhou Kaipu Biotech Co., Ltd.

汇文丽(福建)企业管理有限公司执行董事
 Executive director of Hui Wenli (Fujian) Enterprise Management Co., Ltd.

丽创(福建)生物科技有限公司执行董事
 Executive director of Li Chuang (Fujian) Biotech Co., Ltd.

8.所担任该大陆地区事业地址:
 8. Address of the mainland China area enterprise:

嘉文丽(福建)化妆品有限公司: 福建省漳州台商投资区龙祥路 21 号
 Juwenlee (Fujian) Cosmetics Co., Ltd: No.21, Longxiang Road, Investment Area of Taiwanese Businesses, Zhangzhou, Fujian Province.

漳州开普生物科技有限公司: 漳州台商投资区白礁工业园 13 号通用厂房
 Zhangzhou Kaipu Biotech Co., Ltd: Standard factory, No.3, Baijiao Industrial Area, Investment Area of Taiwanese Businesses, Zhangzhou.

汇文丽(福建)企业管理有限公司: 福建省漳州台商投资区龙祥路 21 号之 1
 Hui Wenli (Fujian) Enterprise Management Co., Ltd: Building 1, No.21, Longxiang Road, Investment Area of Taiwanese Businesses, Zhangzhou, Fujian Province.

丽创(福建)生物科技有限公司: 福建省漳州台商投资区龙祥路 21 号之三
 Li Chuang (Fujian) Biotech Co., Ltd: Building 3, Longxiang Road, Investment Area of Taiwanese Businesses, Zhangzhou, Fujian Province.

9.所担任该大陆地区事业营业项目:
 9. Business items of the mainland China area enterprise:

嘉文丽(福建)化妆品有限公司: 美容护肤产品制造、买卖。
 Juwenlee (Fujian) Cosmetics Co., Ltd: Manufacturing and selling skincare products.

漳州开普生物科技有限公司: 食品制造。
 Zhangzhou Kaipu Biotech Co., Ltd: Food manufacturer.

汇文丽(福建)企业管理有限公司: 一般投资业务。
 Hui Wenli (Fujian) Enterprise Management Co., Ltd: General investment services.

丽创(福建)生物科技有限公司: 美容护肤产品买卖。
 Li Chuang (Fujian) Biotech Co., Ltd: Selling skincare products.

10.对本公司财务业务之影响程度:无重大影响。
 10. Degree of effect on the company's finances and business: None

11.董事如有对该大陆地区事业从事投资者, 其投资金额及持股比例:

	<p>11. If the investor has invested in the mainland China area enterprise, the monetary amount of the director's investment and the director's shareholding ratio: 漳州开普生物科技有限公司, 罗丽芬女士投资金额美金 28 万元(持股比例 80%), 饶焕文先生投资金额美金 7 万元(持股比例 20%)。 Zhangzhou Kaipu Biotech Co., Ltd, Luo Lih-Fen invested \$280,000 (shareholding ratio: 80%), Huanwen Rao invested \$70,000 (shareholding ratio: 20%).</p> <p>12.其他应叙明事项:无。</p> <p>12. Any other matters that need to be specified: None.</p>
--	---

以上数据均由各公司依发言当时所属市场别之规定申报后, 由本系统对外公布, 数据如有虚伪不实, 均由该公司负责。

All data above is released by the system after it is declared by each company in accordance with the regulations of the corresponding market at the time of the speech. If the data is false, the company will be accountable for it.